Fundraising FoxDCVC Bio — 2025 Investments
6 investments dated 2025 · listed companies and verified rows first · show all
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
BiotechData & InfrastructureEnterprise SoftwareMedia & EntertainmentDurham, US
Pieter Burger(Executive Officer, Director)inThomas Kaiser(Executive Officer, Director)in
BoardChristopher Meldrum(Executive Officer, Director)inDennis Langer(Director)
Board seatJohn Hamer· per SEC Form D
AgZen develops real-time monitoring technology for crop spraying, analyzing droplet behavior to help growers and agricultural equipment manufacturers optimize application efficiency.
AgTechAI & Machine LearningFintechHardwareImpact & Social GoodMedia & EntertainmentSomerville, US
Vishnu Jayaprakash(Founder)inKripa Varanasi(Director)inMaher Damak
BoardCarmichael S. Roberts(Director)Justin Kern(Director)
Co-investorsAstanor VenturesMaterial ImpactDCVC (Data Collective)Syngenta Group Ventures
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesMPM BioImpactRA Capital+2 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)inRaymond Camahort(Director)
Co-investorsDCVC (Data Collective)Arkin CapitalLongwood FundNovo Holdings
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)The Column GroupAlexandriaLux Capital
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Draper AssociatesIllumina VenturesLong GamePortal Innovations+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.